MX2013010171A - Antagonistas del receptor de interleucina-1. - Google Patents
Antagonistas del receptor de interleucina-1.Info
- Publication number
- MX2013010171A MX2013010171A MX2013010171A MX2013010171A MX2013010171A MX 2013010171 A MX2013010171 A MX 2013010171A MX 2013010171 A MX2013010171 A MX 2013010171A MX 2013010171 A MX2013010171 A MX 2013010171A MX 2013010171 A MX2013010171 A MX 2013010171A
- Authority
- MX
- Mexico
- Prior art keywords
- binding
- inflammatory
- receptor
- nervous system
- central nervous
- Prior art date
Links
- 102000019223 Interleukin-1 receptor Human genes 0.000 title abstract 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 title abstract 2
- 239000005557 antagonist Substances 0.000 title 1
- 102000000589 Interleukin-1 Human genes 0.000 abstract 3
- 108010002352 Interleukin-1 Proteins 0.000 abstract 3
- 210000003169 central nervous system Anatomy 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102100026018 Interleukin-1 receptor antagonist protein Human genes 0.000 abstract 1
- 101710144554 Interleukin-1 receptor antagonist protein Proteins 0.000 abstract 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 1
- 229940121363 anti-inflammatory agent Drugs 0.000 abstract 1
- 239000002260 anti-inflammatory agent Substances 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000004968 inflammatory condition Effects 0.000 abstract 1
- 230000002757 inflammatory effect Effects 0.000 abstract 1
- 210000002540 macrophage Anatomy 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000028327 secretion Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/545—IL-1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201170120 | 2011-03-14 | ||
| PCT/DK2012/000022 WO2012122985A1 (en) | 2011-03-14 | 2012-03-14 | Antagonists of the interleukin- 1 receptor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013010171A true MX2013010171A (es) | 2013-11-20 |
Family
ID=45876525
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010171A MX2013010171A (es) | 2011-03-14 | 2012-03-14 | Antagonistas del receptor de interleucina-1. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9359405B2 (enExample) |
| EP (1) | EP2686431B1 (enExample) |
| JP (1) | JP6120782B2 (enExample) |
| KR (1) | KR20140012127A (enExample) |
| CN (1) | CN103476933B (enExample) |
| AU (1) | AU2012228769B2 (enExample) |
| BR (1) | BR112013023309A2 (enExample) |
| CA (1) | CA2828504A1 (enExample) |
| ES (1) | ES2600616T3 (enExample) |
| MX (1) | MX2013010171A (enExample) |
| RU (1) | RU2013145283A (enExample) |
| WO (1) | WO2012122985A1 (enExample) |
| ZA (1) | ZA201306744B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL2598526T4 (pl) | 2010-07-29 | 2019-05-31 | Eleven Biotherapeutics Inc | Agoniści i antagoniści receptora typu i chimerycznej interleukiny il-1 |
| KR102017026B1 (ko) * | 2013-01-10 | 2019-09-02 | (주) 수파드엘릭사 | 염증 또는 알러지의 예방 또는 치료용 약학 조성물 및 염증 또는 알러지 개선용 화장료 조성물 |
| CN107693781B (zh) | 2013-03-13 | 2021-11-09 | 巴扎德制药公司 | 用于眼部递送的嵌合细胞因子制剂 |
| JP2016520615A (ja) * | 2013-05-31 | 2016-07-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | アルツハイマー病を処置するためのｉｌ−１アンタゴニストを使用する方法 |
| CN104711214B (zh) * | 2015-04-09 | 2019-02-12 | 武汉联程生物科技有限公司 | 一种大肠杆菌bbm2015001菌株及其用途 |
| WO2017063657A1 (en) | 2015-10-14 | 2017-04-20 | Phlogo Aps | Il1ra-derived peptide antagonist |
| CN110382001A (zh) * | 2017-02-16 | 2019-10-25 | 埃克斯生物科技公司 | 化脓性汗腺炎的治疗 |
| US12216128B2 (en) | 2018-04-12 | 2025-02-04 | Mayo Foundation For Medical Education And Research | Methods for guiding therapy decisions in seizure disorders |
| KR102022118B1 (ko) * | 2019-01-07 | 2019-09-18 | 주식회사 아스트로젠 | 중추신경계 질환의 예방 또는 치료용 세린 유도체 화합물 |
| ES3026437T3 (en) * | 2021-07-13 | 2025-06-11 | Serodus Aps | Il1ra derived peptides for treatment of diabetic nephropathy |
| CN114177295B (zh) * | 2021-12-16 | 2023-09-19 | 上海市第五人民医院 | 白细胞介素1受体拮抗剂治疗非酒精性脂肪性肝病的应用 |
| CN116144668A (zh) * | 2023-02-13 | 2023-05-23 | 杭州吉倍思生物制药有限公司 | 人il-1r1基因、蛋白、同源二聚体蛋白质与用途 |
| AU2024255810A1 (en) * | 2023-04-14 | 2025-11-13 | Merck Sharp & Dohme Llc | A cyclic peptide for trapping interleukin-1 beta |
| WO2025101453A1 (en) * | 2023-11-07 | 2025-05-15 | University Of Washington | De novo design of potent minibinder antagonists of il-6r, gp130, and il1-r1 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU215434B (hu) | 1988-05-27 | 1999-04-28 | Synergen Inc. | Eljárás interleukin-1 inhibitorok, ezeket kódoló DNS-szekvenciák, vektorok és gazdasejtek előállítására |
| US6858409B1 (en) | 1988-05-27 | 2005-02-22 | Amgen Inc. | Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors |
| US6159460A (en) | 1988-05-27 | 2000-12-12 | Amgen Inc. | Method for treating interleukin-1 mediated diseases |
| US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
| EE03451B1 (et) * | 1994-07-05 | 2001-06-15 | Steeno Research Group A/S | Immunomodulaatorid |
| IT1269989B (it) | 1994-09-21 | 1997-04-16 | Dompe Spa | Antagonisti recettoriali di il-1 ad aumentata attivita' inibitoria |
| IT1270662B (it) | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
| DE19919148A1 (de) * | 1999-04-27 | 2000-11-16 | Wieser Raimund J | Von Interleukin 12 abgeleitete Peptid-Homodimere und Peptid-Heterodimere |
| CN1549723A (zh) * | 2001-02-06 | 2004-11-24 | Ĭ��ר������˾ | 免疫原性减弱的经修饰白介素-1受体拮抗剂(il-1ra) |
| EP1998266A3 (en) * | 2001-02-19 | 2009-02-11 | Merck Patent GmbH | Method for identification of T-cell epitopes and use for preparing molecules with reduced immunogenicity |
| US20030083301A1 (en) | 2001-09-06 | 2003-05-01 | Board Of Regents, The University Of Texas System | Therapeutic treatments for spinal cord injury via blockade of interleukin-1 receptor |
| KR20050042082A (ko) * | 2002-05-31 | 2005-05-04 | 시젠 피티와이 리미티드 | 막 투과 서열로부터 유도된 자가 융합 또는 자가 응집단백질 |
| US20050159590A1 (en) | 2003-08-25 | 2005-07-21 | Galit Rotman | Variants of interleukin-1 receptor antagonist: compositions and uses thereof |
| US7482323B2 (en) | 2004-03-04 | 2009-01-27 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonist and uses thereof |
| US7674464B2 (en) | 2004-03-04 | 2010-03-09 | The University Of Tennessee Research Foundation | Intracellular interleukin-1 receptor antagonists |
| JP2007531738A (ja) | 2004-04-02 | 2007-11-08 | アムジエン・インコーポレーテツド | ＩＬ−１ｒａの凝集を低下させる方法 |
| ES2395087T3 (es) | 2004-05-05 | 2013-02-08 | Valorisation-Recherche, Société en Commandite | Antagonistas del receptor de interleuquina-1, composiciones y métodos de tratamiento |
| US8618054B2 (en) | 2004-05-05 | 2013-12-31 | Valorisation-Rechereche Société en Commandite | Interleukin-1 receptor antagonists, compositions, and methods of treatment |
| EP1885855A4 (en) | 2005-05-05 | 2009-03-04 | Valorisation Hsj Soc En Comman | CYTOKIN RECEPTOR MODULATORS AND USES THEREOF |
| US7736860B2 (en) | 2006-11-09 | 2010-06-15 | Univeristy Of Massachusetts | Methods of identifying compounds for the treatment of sterile inflammation |
| EP2187900B1 (en) | 2007-08-16 | 2016-11-09 | The Schepens Eye Research Institute, Inc. | Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues |
| WO2009048961A1 (en) | 2007-10-08 | 2009-04-16 | Anaphore, Inc. | Trimeric il-1ra |
| CN101255197B (zh) * | 2008-03-28 | 2012-01-25 | 浙江海正药业股份有限公司 | 血清白蛋白与白介素1受体拮抗剂的融合蛋白及应用 |
| PL2393828T3 (pl) * | 2009-02-03 | 2017-06-30 | Amunix Operating Inc. | Wydłużone rekombinowane polipeptydy i zawierające je kompozycje |
-
2012
- 2012-03-14 CN CN201280013172.1A patent/CN103476933B/zh not_active Expired - Fee Related
- 2012-03-14 EP EP12710122.8A patent/EP2686431B1/en active Active
- 2012-03-14 US US14/003,824 patent/US9359405B2/en active Active
- 2012-03-14 AU AU2012228769A patent/AU2012228769B2/en not_active Ceased
- 2012-03-14 RU RU2013145283/10A patent/RU2013145283A/ru not_active Application Discontinuation
- 2012-03-14 ES ES12710122.8T patent/ES2600616T3/es active Active
- 2012-03-14 WO PCT/DK2012/000022 patent/WO2012122985A1/en not_active Ceased
- 2012-03-14 CA CA2828504A patent/CA2828504A1/en not_active Abandoned
- 2012-03-14 MX MX2013010171A patent/MX2013010171A/es not_active Application Discontinuation
- 2012-03-14 BR BR112013023309A patent/BR112013023309A2/pt not_active IP Right Cessation
- 2012-03-14 JP JP2013558307A patent/JP6120782B2/ja active Active
- 2012-03-14 KR KR1020137026679A patent/KR20140012127A/ko not_active Withdrawn
-
2013
- 2013-09-09 ZA ZA2013/06744A patent/ZA201306744B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US9359405B2 (en) | 2016-06-07 |
| ZA201306744B (en) | 2014-11-26 |
| AU2012228769A1 (en) | 2013-10-10 |
| BR112013023309A2 (pt) | 2017-09-19 |
| US20140073556A1 (en) | 2014-03-13 |
| EP2686431B1 (en) | 2016-08-03 |
| WO2012122985A1 (en) | 2012-09-20 |
| EP2686431A1 (en) | 2014-01-22 |
| CA2828504A1 (en) | 2012-09-20 |
| AU2012228769B2 (en) | 2016-09-08 |
| ES2600616T3 (es) | 2017-02-10 |
| JP2014510082A (ja) | 2014-04-24 |
| NZ615710A (en) | 2015-10-30 |
| JP6120782B2 (ja) | 2017-04-26 |
| RU2013145283A (ru) | 2015-04-20 |
| CN103476933A (zh) | 2013-12-25 |
| KR20140012127A (ko) | 2014-01-29 |
| CN103476933B (zh) | 2016-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013010171A (es) | Antagonistas del receptor de interleucina-1. | |
| UY33801A (es) | COMPUESTOS SUSTITUIDOS DE N-(1H-INDAZOL-4IL)IMIDAZO[1,2-a]PIRIDIN-3-CARBOXAMIDA COMO INHIBIDORES DE LA TIROSINA QUINASA RECEPTORA DE TIPO III | |
| EA201070328A1 (ru) | Соединения триазолопиридина и их применение в качестве ингибиторов ask | |
| EA201391584A1 (ru) | Новое соединение, предназначенное для лечения дегенеративных и воспалительных заболеваний | |
| CL2013000930A1 (es) | Anticuerpo para interleuquina 17 (il-17); uso de dicho anticuerpo para tratar soriasis usando antagonistas de il-17. | |
| UA108222C2 (xx) | СПОЛУКИ ЗАМІЩЕНОГО N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗОЛ$1,2-а]ПІРИДИН-3-КАРБОКСАМІДУ ЯК ІНГІБІТОРИ cFMS | |
| EA201390711A1 (ru) | Гидроксиамидные соединения пиримидина в качестве ингибиторов деацетилаз белков и способы их применения | |
| EA201892339A2 (ru) | Несиалированный выделенный полипептид, способ получения указанного полипептида и фармацевтическая композиция для лечения воспалительного заболевания | |
| UA106318C2 (ru) | Производный полипептид il-2 с агонистической активностью для лечения рака и хронических инфекций | |
| EA201100524A1 (ru) | Азаиндазолы в качестве антагонистов рецептора ccr1 | |
| EA201270100A1 (ru) | Пиримидиноны в качестве ингибиторов pi3k | |
| EA201390803A1 (ru) | Ингибиторы бромодомена и их применение | |
| PH12012501783A1 (en) | Heterocyclic inhibitors of histamine receptors for the treatment of disease | |
| UA109667C2 (xx) | Похідні хіназолін-4(3h)-ону, що використовуються як інгібітори pi3-кінази | |
| MY183974A (en) | Il17 and ifn-gamma inhibition for the treatment of autoimmune inflammation | |
| MX353762B (es) | Inhibicion de il17 e ifn-gamma para el tratamiento de inflamacion autoinmune. | |
| EP2595482A4 (en) | ALDOSTERONSYNTHASEHEMMER | |
| EA201170218A1 (ru) | Лечение воспалительных заболеваний бета-дефенсинами млекопитающих | |
| PH12013502611A1 (en) | Trpm8 antagonists and their use in treatments | |
| EA201270790A1 (ru) | Соединение пиперидинила в качестве модулятора активности хемокинового рецептора | |
| EA200970818A1 (ru) | Гетероциклические соединения, содержащие их композиции и способы их применения | |
| MY157319A (en) | Inhibitors of protein tyrosine kinase activity | |
| EA201591391A1 (ru) | Производное 2-ациламинотиазола или его соль | |
| EA201491737A1 (ru) | Композиции и способы регулирования роста волос | |
| TR201910983T4 (tr) | Tnf aktivitesinin modülatörleri olarak imidazotiazol türevleri. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights |
Owner name: PHLOGO APS |
|
| FA | Abandonment or withdrawal |